Pharsight

Yondelis patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8895557 JANSSEN PRODS Pharmaceutical formulations of ecteinascidin compounds
Jan, 2028

(3 years from now)

US8895557

(Pediatric)

JANSSEN PRODS Pharmaceutical formulations of ecteinascidin compounds
Jul, 2028

(4 years from now)

Yondelis is owned by Janssen Prods.

Yondelis contains Trabectedin.

Yondelis has a total of 2 drug patents out of which 0 drug patents have expired.

Yondelis was authorised for market use on 23 October, 2015.

Yondelis is available in powder;intravenous dosage forms.

Drug patent challenges can be filed against Yondelis from 23 April, 2022.

The generics of Yondelis are possible to be released after 07 July, 2028.

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 23, 2020
Orphan Drug Exclusivity(ODE) Oct 23, 2022
Orphan Drug Exclusivity(ODE-100) Oct 23, 2022
M(M-232) Jun 29, 2021
Pediatric Exclusivity(PED) Apr 23, 2023

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using TRABECTEDIN ingredient

NCE-1 date: 23 April, 2022

Market Authorisation Date: 23 October, 2015

Treatment: NA

Dosage: POWDER;INTRAVENOUS

How can I launch a generic of YONDELIS before it's drug patent expiration?
More Information on Dosage

YONDELIS family patents

Family Patents